

Press release

May 7, 2025

Curasight A/S selects CRO to run Phase 1 trial with uTREAT® in brain cancer

- Appointment of clinical CRO marks further step in progress in development of uTREAT as a potential new therapeutic solution for aggressive brain cancer (Glioblastoma)
- The Phase 1 trial is part of Curasight's theranostic approach combining uTRACE and uTREAT, seeking to improve diagnosis and provide more gentle and efficient treatment of brain cancer patients

Copenhagen, May 7, 2025 - Curasight A/S ("Curasight" or "the Company" – TICKER: CURAS) announce it has signed a Master Service Agreement and Work Order with Premier Research, LLC, an experienced international Clinical Research Organization serving the pharmaceutical industry, to run the phase 1 trial investigating uTREAT® in improving the treatment of brain cancer patients.

The Phase 1 trial is an important part of advancing Curasight's theranostic platform and also marks Curasight as a therapeutic company.

"We are very pleased to be working with Premier Research – a globally represented Clinical Research Organization and a company with proven experience in the very specialized field of conducting international diagnostic and therapeutic trials with radiopharmaceutical agents. We believe Premier Research is the optimal partner to secure the efficient and effective execution of this trial, which is an important element of our therapeutic platform uTREAT in brain cancer" said Curasight's CEO Ulrich Krasilnikoff.

"We are delighted to partner with Curasight – a leader in the field of theranostics - we look forward to working with their innovative radiopharmaceutical technology. We are confident we can deliver a high level of operational excellence to ensure the optimal execution of this important Phase 1 trial with uTREAT" said Premier Research's CEO John Ratliff.

About the Phase 1 trial with uTREAT in brain cancer

The primary objective of this phase 1 trial is to investigate Curasight's uTREAT ligand as a treatment option of cancer patients diagnosed with Glioblastoma. Participants in the trial are patients with verified or suspected GBM scheduled for brain surgery. The trial design is informed from research and earlier studies with uTRACE® as well as protocol discussions with Key Opinion Leaders.

About the uPAR therapeutic platform

The uTREAT platform is part of Curasight's uPAR theranostic solution, made up of its uTRACE diagnostic technology and its uTREAT targeted treatment technology. In brain cancer (Glioblastoma), both uTRACE (diagnostic) and uTREAT (treatment) is developed.

About Premier Research, LLC

Premier Research, LLC, a leading provider of clinical research and consulting services for the life sciences industry, offers strategic solutions across the entire product development lifecycle, from pre-clinical through commercialization, leveraging innovative study design and full-service clinical trial management, specializing in nuclear medicine with a strong emphasis on oncology, neuroscience, and therapeutic applications, and possessing extensive experience in researching glioblastoma treatment agents.



PROVIDING ANSWERS FOR CANCER PATIENTS

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60

E-mail: uk@curasight.com

www.curasight.com

Curasight is a clinical development company based in Copenhagen, Denmark. The Company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging (uTRACE®) and Radioligand Therapy (uTREAT®) Theranostic Platform targeting the urokinase-type plasminogen activator receptor ("uPAR"). The technology is seeking to improve diagnosis and provide more gentle and efficient treatment of multiple cancer types.